

Nizoral

TRADE MARK

ketoconazole

oral therapy for all common fungal infections

Vaginal candidosis:	In all dermatological and in systemic fungal infections:
2 tablets once daily (with food) for 5 days	1 tablet daily (with food) until complete symptomatic and mycological cure is obtained

Not all indications are as yet approved in all countries.

PRESCRIBING INFORMATION

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and k/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults, of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed.

Side-effects, precautions, contra-indications: contra-indicated in pregnancy. For maximal absorption, Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂ blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped.



Janssen Pharmaceutica
B-2340 Beerse, Belgium

The British Council International Medical Courses

IMMUNITY TO PARASITES

**27 November-9 December 1983
in London/Cambridge**

This course will aim to illustrate methods currently employed to elucidate the nature of immune reactions to protozoan and metazoan parasites. The techniques used to isolate and characterise functionally important antigenic components of these complex organisms will be emphasised. The Director of Studies will be **Professor Sydney Cohen** of the Department of Chemical Pathology, Guy's Hospital Medical School, University of London. The course is intended for senior immunologists, parasitologists, molecular biologists and clinicians with several years' experience in the diagnosis and management of parasitic disease.

Fee £740 (Residential), £430 (Non-residential).

GASTROINTESTINAL ENDOSCOPY

4-9 December 1983 in London

This course follows the successful British Council course held in London in 1981. It will commence with an introductory session on the basic aspects of diagnostic and therapeutic digestive endoscopy and will then concentrate on live case demonstrations with related discussions on indications, instrumentation and technique. There will also be demonstrations of interventional radiology. The emphasis will be on the practical aspects of endoscopy but other important and related subjects will be covered. The Director of Studies will be **Dr Paul Salmon**, Consultant Physician at University College Hospital, London and Senior Clinical Lecturer in Gastroenterology at University College London. Course members will be expected to have a working knowledge of gastrointestinal endoscopy and to be reasonably experienced.

Fee £320 (Residential), £190 (Non-residential).

RENAL TRANSPLANTATION

15-27 January 1984 in Glasgow

The aim of this course is to cover in depth the theoretical and practical aspects of renal transplantation as currently practised in Britain. Particular attention will be paid to the immunological aspects of transplantation. The important points in the medical and surgical management of the patient will be dealt with including a session on dialysis. The Directors of Studies will be **Dr J D Briggs** and **Mr D N H Hamilton** of the Transplant Unit in the Western Infirmary, Glasgow and **Dr Heather Dick** of the Department of Immunology in Glasgow Royal Infirmary. The course will be aimed at general surgeons, urologists and physicians working in transplant units. It is expected that those applying will already have experience in renal transplantation.

Fee £690 (Residential), £405 (Non-residential).

THE BIOLOGICAL BASIS OF RADIOTHERAPY

5-17 February 1984 in London

This will be the second British Council course on this subject, the first, held in London in early 1982, having been regarded by the course members as both highly stimulating and extremely successful. The Directors of Studies will be **Professor G E Adams** of the Medical Research Council, Radiobiology Unit and **Professor M J Peckham** of the Institute of Cancer Research and the Royal Marsden Hospital. The course is designed for professors and heads of departments of radiotherapy and radiobiology, clinicians with a major interest in radiation oncology and pharmacologists working with radiosensitisers and chemotherapy.

Fee £715 (Residential), £415 (Non-residential).

ADVANCED PAEDODONTICS

18-30 March 1984 in London/Newcastle upon Tyne

This course aims to review current clinical practice, prevention of dental disease and certain aspects of research in the field of paediatric dentistry. The first part of the course will be undertaken in the University of London and a second component will be held in the University of Newcastle. It will be directed jointly by **Professor G B Winter**, Head of the Department of Children's Dentistry at the Institute of Dental Surgery, University of London and **Professor J J Murray**, Head of the Department of Child Dental Health at the University of Newcastle. The course is designed for senior clinicians and academics involved in the practice of paediatric dentistry.

Fee £695 (Residential), £405 (Non-residential)

BREAST CANCER: AN INTERNATIONAL SEMINAR

8-14 April 1984 in Edinburgh

This seminar is designed to present the state of up-to-date knowledge on clinical aspects of human cancer of the breast. It will include ten sessions of three and a half to four hours which will present in depth consideration of selected topics, including the natural history of the disease, epidemiological factors, early diagnosis, prediction of spread, local and systemic treatment and the management of advanced disease. The Directors of Studies will be **Professor A P M Forrest** and **Mr O Eremin** of the Department of Clinical Surgery in the University of Edinburgh. The seminar is open to surgeons, radiation or medical oncologists, pathologists and all others with special knowledge and experience of breast disease.

Fee £415 (Residential), £240 (Non-residential).

EPIDEMIOLOGICAL METHODS

29 April-11 May 1984 in Southampton

This course aims to provide an understanding of the basic epidemiological methods used in medical research. It will also cover some aspects of statistics that are particularly relevant to this field. Examples of epidemiological studies will include some from health services research as well as from the descriptive epidemiology of diseases and studies of the causation of disease. The Director of Studies will be **Professor W E Waters**, Professor of Community Medicine in the University of Southampton. The course is designed for clinical, industrial and administrative medical officers and public health officials, particularly those with medical qualifications. It may also be of use to others involved in socio-medical research. No previous knowledge of epidemiology or statistics will be assumed.

Fee £695 (Residential), £405 (Non-residential).

CHILDREN'S ORTHOPAEDIC SURGERY

12-19 May 1984 in Edinburgh

The aim of this course is to review current management of, and to present recent advances in, children's orthopaedic surgery. It follows the successful course held in Edinburgh in 1982. Topics to be discussed will include: congenital deformities, inflammatory and infectious diseases, neuromuscular disorders, analysis of gait, bone tumours, spinal disorders including scoliosis, and disorders of the hip, knee and foot. The Director of Studies will be **Professor S P F Hughes** of the Department of Orthopaedic Surgery in the University of Edinburgh. The course is intended for trained children's orthopaedic surgeons.

Fee £495 (Residential), £290 (Non-residential).

FURTHER INFORMATION AND APPLICATION FORMS CAN BE OBTAINED FROM YOUR LOCAL OVERSEAS REPRESENTATIVE OF THE BRITISH COUNCIL OR FROM COURSES DEPARTMENT, THE BRITISH COUNCIL, 65 DAVIES STREET, LONDON W1Y 2AA.

fucidin[®]

sodium fusidate

knows
no barriers
in staphylococcal infection

Prescribing Information.

Dosage: FUCIDIN TABLETS (250mg sodium fusidate). 500mg 3 times daily.

Adverse reactions and precautions: In some patients taking Fucidin, a reversible jaundice has been reported, most frequently in subjects receiving intravenous therapy. In general, oral therapy should be instituted as soon as possible. If the jaundice persists, the drug should be withdrawn, following which the serum bilirubin will invariably return to normal. Fucidin is excreted mainly in the bile and liver function tests should be carried out in patients with liver dysfunction when used for prolonged periods and when administered in conjunction with other drugs which may compete for the same excretory pathway. Gastro-intestinal upset occurs in some patients taking oral Fucidin. This can be minimised by taking the tablets with food.

Product Licence Number: 0043 5000

Basic N.H.S. Price: For an adult £3.87 per day ex bottle of 100

Also available as Fucidin Suspension and Fucidin for Intravenous Infusion.



Leo Laboratories Limited
Longwick Road, Princes Risborough.
Aylesbury, Bucks. HP17 9RR

® Fucidin is a trademark

